EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma

EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma

BackgroundRegorafenib, a tyrosine kinase inhibitor (TKI), is used in the treatment of unresectable hepatocellular carcinoma (HCC). However, the occurrence of acquired resistance limits its antitumor efficacy. While multiple studies have highlighted the crucial role of bypass activation in acquired T...

Full description

Bibliographic Details
Main Authors: Lili Hu, Weiwei Shi, Kua Liu, Ding Ma, Qilei Xin, Zhongxia Wang, Yin Cao, Guang Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Medicine
Subjects:
regorafenib
acquired resistance
EGFR
bypass activation
combination therapy
HCC
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2024.1464610/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2024.1464610/full

Similar Items